Breaking News

Lykos Therapeutics cuts 75% of staff after FDA rejects MDMA-assisted therapy 

August 15, 2024
Pharmalot Columnist, Senior Writer
Adobe

STAT+ | Lykos Therapeutics cuts 75% of staff after FDA rejects MDMA-assisted therapy

The company also announced that Rich Doblin, the company's founder, would step down from its board.

By Meghana Keshavan


Medicare drug price negotiation didn't benefit Biden — but it may help Harris

Medicare negotiating lower drug prices is popular among voters. Kamala Harris cast the decisive tie-breaking vote, and every Republican voted against it.

By John Wilkerson and Rachel Cohrs Zhang


STAT+ | What do Biden's drug price comparisons reveal? Not much

Medicare negotiations will lower drug prices, but precise savings are hard to estimate in a health care business mix of insurers, PBMs and drug companies.

By Rachel Cohrs Zhang



Novolog insulin is one of 10 drugs that received negotiated prices.
Rich Pedroncelli/AP

STAT+ | Medicare announces drug prices for historic first round of negotiations

Inflation Reduction Act negotiations cover 10 drugs: Eliquis, Xarelto, Januvia, Jardiance, Enbrel, Imbruvica, Farxiga, Entresto, Stelara and NovoLog

By Rachel Cohrs Zhang


Arthritis patients resort to an inconvenient Medicare workaround to avoid pricey drugs

Switching from Humira or Xeljanz reduces out-of-pocket expenses but requires lengthy infusions and risks side effects.

By Joseph Howlett and Andrea Tamayo


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Pharmalot? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2024, All Rights Reserved.

No comments